Table 1.

General characteristics of women with BCa with Aromatase Inhibitor (AI) Use and controls at baseline

Cancer-related responses	Frequencies Mean ± SD	Percentage Range
Age at breast cancer diagnosis in years	59.3 ± 7.1	42 – 73
Time since breast cancer diagnosis in months	15.1 ± 6.1	8 – 19
AI duration in months	5.7 ± 3.1	2 – 11
	N	%
Tumor stage at diagnosis:
- Stage I	15	51.7
- Stage II	9	31.0
- Stage III	5	17.3
Breast cancer treatment	N	%
Prior adjuvant chemotherapy:
Yes	18	62.1
No	11	37.9
Number of months between end of chemotherapy and baseline survey:
4–6 months	4	22.2
>6 months – 9 months	6	33.3
>9 months – 12 months	4	22.2
> 12 months	4	22.2
Prior radiation:
Yes	26	89.6
No	3	10.4
Prior Tamoxifen use:
Yes	5	17.2
No	24	82.8
Distribution of AIs:
Anastrozole	20	68.9
Exemestane	2	6.9
Letrozole	7	24.2
Breast Cancer and Control group
Medications intake and systemic disease	AI (n=29) N (%)	Control (n=29) N (%)
Bisphosphonate Use:
- Yes	11(38%)	5(17%)
Coexisting systemic diseases
Number of patients, (%)	20(68%)	16(55%)
Daily Medications
Number of patients, (%)	29(100%)*	22(76%)
Number of medications-Mean, SD	2.3±0.9	1.7±1.4
Range	(1–5)	(0–5)
Number of patients, (%)	20(69%)	18(62%)
Potentially xerogenic medications-Mean, SD	1.02±1.0	0.8±0.9
Range	(0–4)	(0–3)

AI –Aromatase inhibitors

^*All BCa patients took an AI daily